GlassScriptPhysician profile
Sarah Thomas
NPI 1689059032
$9,280.65
in general payments reported to CMS, 2019-2025
30 companies · $1,764 in 2025
The $1,764 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $739 · 2022: $3,107 · 2023: $2,066 · 2024: $1,606 · 2025: $1,764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,434.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,007.92 | 2021-2025 | |
| Boston Scientific Corporation | $1,768.85 | 2021-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Artisan |
| Relievant Medsystems, INC. | $1,244.01 | 2022 | |
| Pfizer INC. | $350.04 | 2021-2025 | |
| Saluda Medical Americas, INC. | $280.10 | 2025 | Evoke |
| Biohaven Pharmaceutical Holding Company LTD. | $259.75 | 2022 | |
| Collegium Pharmaceutical, INC. | $253.91 | 2021-2025 | Belbuca, Nucynta |
| International Rehabilitative Sciences, INC | $224.49 | 2023-2025 | Rs 4i Plus Sequential Stimulator, Rs-4i Plus With Intersperse |
| Scilex Pharmaceuticals INC. | $203.23 | 2022-2025 | Ztlido |
| Azurity Pharmaceuticals, INC. | $182.55 | 2023 | Horizant |
| Ibsa Pharma INC. | $177.52 | 2021-2025 | Tirosint, Tirosint, Licart |
| Vertex Pharmaceuticals Incorporated | $157.18 | 2024-2025 | |
| Si-Bone, INC. | $148.24 | 2024-2025 | |
| Lilly USA, LLC | $142.75 | 2024-2025 | Emgality |
| Kowa Pharmaceuticals America, INC. | $131.62 | 2023 | Seglentis |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $128.80 | 2021-2022 | |
| Spr Therapeutics, INC | $123.36 | 2023-2025 | Sprint Pns System |
| Biohaven Pharmaceuticals, INC. | $113.18 | 2021 | |
| Vertos Medical, INC. | $73.95 | 2022-2024 | Mild Device Kit |
| Allergan, INC. | $66.72 | 2021-2022 | |
| Fidia Pharma USA INC. | $57.41 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $34.89 | 2024 | Dysport |
| Lundbeck LLC | $22.93 | 2025 | Vyepti |
| Medtronic, INC. | $22.67 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $21.47 | 2024 | Zilretta, Iovera, Exparel |
| Arbor Pharmaceuticals, INC. | $19.16 | 2022 | |
| Nalu Medical, INC. | $17.75 | 2021 | |
| Almatica Pharma LLC | $16.79 | 2021 | |
| Bioventus LLC | $15.73 | 2025 | Supartz Fx Sodium Hyaluronate |
| Biodelivery Sciences International, INC. | $13.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.